Citigroup Forecasts Strong Price Appreciation for Albemarle (NYSE:ALB) Stock

Albemarle (NYSE:ALB) had its price target raised by equities researchers at Citigroup from $210.00 to $225.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the specialty chemicals company’s stock. Citigroup’s target price would indicate a potential upside of 10.45% from the company’s previous close.

Several other research analysts have also weighed in on ALB. Robert W. Baird increased their price objective on shares of Albemarle from $210.00 to $236.00 in a report on Thursday. BMO Capital Markets lifted their price target on shares of Albemarle from $145.00 to $210.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Royal Bank Of Canada lifted their price target on shares of Albemarle from $216.00 to $245.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Albemarle from $185.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, HSBC upped their price objective on shares of Albemarle from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Albemarle presently has a consensus rating of “Hold” and an average target price of $189.04.

Albemarle Price Performance

Shares of ALB traded up $5.37 during trading hours on Friday, reaching $203.72. The company had a trading volume of 3,125,911 shares, compared to its average volume of 2,600,313. The firm has a 50 day simple moving average of $179.56 and a 200-day simple moving average of $154.41. The company has a current ratio of 2.23, a quick ratio of 1.57 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $24.02 billion, a price-to-earnings ratio of -59.74, a PEG ratio of 1.38 and a beta of 1.36. Albemarle has a 12-month low of $53.70 and a 12-month high of $221.00.

Albemarle (NYSE:ALB) last announced its quarterly earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $1.71. The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. Albemarle had a negative net margin of 5.00% and a positive return on equity of 5.20%. The business’s revenue was up 32.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.18) EPS. Research analysts expect that Albemarle will post 8.72 earnings per share for the current year.

Insider Buying and Selling

In other Albemarle news, CEO J Kent Masters sold 11,783 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $170.81, for a total value of $2,012,654.23. Following the sale, the chief executive officer directly owned 134,628 shares in the company, valued at approximately $22,995,808.68. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.42% of the company’s stock.

Institutional Trading of Albemarle

Several institutional investors and hedge funds have recently bought and sold shares of ALB. AQR Capital Management LLC raised its holdings in Albemarle by 25.5% during the 1st quarter. AQR Capital Management LLC now owns 3,223 shares of the specialty chemicals company’s stock worth $229,000 after buying an additional 654 shares during the period. Integrated Wealth Concepts LLC raised its holdings in Albemarle by 26.2% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,798 shares of the specialty chemicals company’s stock worth $346,000 after buying an additional 996 shares during the period. United Services Automobile Association acquired a new stake in Albemarle during the 1st quarter worth about $208,000. Empowered Funds LLC acquired a new stake in Albemarle during the 1st quarter worth about $411,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Albemarle by 536.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 573 shares of the specialty chemicals company’s stock worth $36,000 after buying an additional 483 shares during the period. Institutional investors and hedge funds own 92.87% of the company’s stock.

Key Headlines Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Q1 results materially beat expectations — Albemarle reported $2.95 EPS vs. $1.24 consensus and revenue of $1.43B (up ~33% YoY), driven by higher lithium pricing and volumes and a ~70% lift in Energy Storage sales. This is the main driver behind the stock’s upward move. Albemarle Reports First Quarter 2026 Results
• Positive Sentiment: Earnings-call tone and outlook signaled strong momentum — management commentary and the call transcript emphasized improving lithium market dynamics and operational momentum, supporting higher earnings visibility. Earnings Call Transcript
• Positive Sentiment: Robert W. Baird raised its price target to $236 (material upside vs. recent levels), providing a bullish analyst endorsement that likely amplified buying. Baird Adjusts ALB Price Target
• Neutral Sentiment: Mizuho raised its target to $205 and kept a neutral rating — a modest upgrade that affirms the beat but implies limited near-term upside from that house. Mizuho Price Target
• Neutral Sentiment: Albemarle updated FY‑2026 revenue guidance to roughly $5.7–$6.0B (in line with consensus), which reduces uncertainty but wasn’t a clear upside surprise on its own. Q1 Presentation / Guidance
• Neutral Sentiment: Zacks and other outlets compared Albemarle vs. peers for value and highlighted the company’s improved operating metrics — useful for longer-term investors but less immediately market-moving than the beat and upgrades. LYB or ALB: Value Comparison
• Negative Sentiment: Wells Fargo raised its target to $200 but maintained an “equal weight” rating — their target implies limited upside/possible slight downside versus recent levels, a cautionary signal for some investors. Wells Fargo View

Albemarle Company Profile

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.